Fail fast is not a cultural problem. It is a capital allocation problem.

The pharmaceutical industry does not lack ambition. It lacks early signal clarity.

More than 90% of drugs entering clinical trials fail. Behind that statistic sits a stark economic reality: billions of dollars are committed each year to programmes that collapse due to safety, efficacy, or biological fragility that existed long before the first patient was dosed.

For decades, the industry has treated this attrition as an unavoidable cost of innovation. Biology is complex. Disease is heterogeneous. Clinical research is inherently risky. All of that is true. But embedded within that 90% failure rate is a more uncomfortable truth: many of these risks were detectable earlier, if we had interrogated human biology with greater fidelity.

“Fail fast” sounds disciplined. Terminate weak assets early. Reallocate capital. Improve returns. But you cannot fail early if you cannot see risk clearly.

Confusing activity with insight

Drug development still relies heavily on sequential experimentation and animal models as proxies for human systems. These tools have advanced science profoundly, yet, their translational reliability is constrained. Differences in metabolism, immune signalling, target biology, and disease architecture create blind spots that only resolve in humans.

The industry often confuses activity with insight. More studies. More models. More datasets. Yet, when those systems do not adequately represent human physiology, additional experimentation may simply compound false confidence. Programmes advance not because they are truly de-risked, but because they have not yet been disproven.

That delay is expensive. A Phase 2 failure can expose $50 million to $150 million. A Phase 3 failure can exceed $300 million when time, infrastructure, and organisational cost are included. Even successful programmes often absorb avoidable capital through late dose adjustments, reformulations, or indication pivots that could have been anticipated earlier.

These figures understate the broader impact: pipeline gaps created by late stage attrition, leadership distraction, equity dilution, lost patent life, and erosion of investor trust. Capital tied up in fragile programmes is capital unavailable for higher conviction science.

This is not simply scientific inefficiency. It is portfolio drag. Investors accept failure. What they resist is late clarity. Programmes often advance because uncertainty remains unresolved, not because conviction is strong.

Ambiguity becomes a bridge to the next milestone. But ambiguity also compounds exposure. Each successive phase increases sunk cost, operational complexity, and reputational risk. By the time clarity arrives, the capital at stake is multiples of what it was at the outset.

AI's economic role

Artificial intelligence has been framed primarily as a discovery accelerator. Its more meaningful economic role may lie upstream.

Acceleration without resolution does not improve returns. Moving molecules into development faster does not inherently enhance portfolio quality. What matters is whether early stage decisions are made with deeper biological integration and predictive discipline.

The critical question in development is not whether a molecule binds a target. It is whether the biology will behave as expected in a human system at a viable dose without unacceptable toxicity. That question is inherently integrative. It requires understanding exposure, tissue distribution, pathway modulation, compensatory signalling, and patient variability simultaneously. Historically, these dimensions have been explored in isolation, producing fragmented insight and delayed risk recognition.

When mechanistic biology is integrated with machine learning and computational simulation, drug behaviour can be modelled within human physiology before substantial capital is committed. Exposure dynamics, organ level effects, safety liabilities, and biomarker trajectories can be assessed in a unified framework, rather than inferred sequentially.

This does not eliminate uncertainty. Drug development will always carry risk. But it changes the timing of clarity. It allows fragility to surface when programmes are still capital light, teams are adaptable, and strategic options remain open.

Even modest improvements in early predictive resolution can materially shift portfolio economics.

If stronger clinical outcome intelligence prevents even 10% to 15% of programmes from advancing into Phase 2 or Phase 3 only to fail, the impact is significant. Capital is deployed with greater precision. Late stage attrition declines. Timelines compress. Opportunity cost falls.

The compounding effect is powerful. Fewer late stage failures mean fewer emergency financings, fewer restructurings, and fewer abrupt pipeline resets. Leadership teams allocate resources intentionally, rather than reactively. Investors reward predictability, even in a high risk domain. That is fail fast in economic terms.

Seeing fragility sooner

Regulators are increasingly open to in silico and model informed approaches. Investors are scrutinising R&D productivity with greater intensity. Biotechs face constrained financing environments. Large pharma confronts sustained patent cliffs.

In this environment, tolerance for opaque risk is narrowing. Capital markets are less forgiving of prolonged ambiguity. Boards demand clearer justification for advancement decisions. The historical model of absorbing late stage attrition as a cost of doing business is increasingly misaligned with financial reality.

Incremental process improvements are insufficient. Early translational clarity becomes strategic infrastructure.

Failing fast is not about embracing failure. It is about seeing fragility sooner.

It is about aligning capital deployment with biological insight. It is about ensuring that progression through development reflects rising conviction, not accumulated momentum. It is about converting uncertainty from a downstream shock into an upstream filter.

In a capital intensive industry, better foresight is not optional. It is financial discipline.

About the author

Dr Jo Varshney is the founder and CEO of VeriSIM Life, an AI-enabled biotechnology company focused on improving the predictability of drug development through biology-driven AI and mechanistic modelling. The company’s platform integrates biological modelling and AI to assess translational risk before drugs enter the clinic, aiming to reduce attrition, cost, and unnecessary animal use. Dr Varshney is a frequent speaker on translational AI and innovation in drug development and has been recognised as one of the Most Influential Women in Business by the San Francisco Business Times and named to the 100 Women in AI list. Her work centres on a simple premise: clinical success should be engineered, not left to chance.